Tecom embarks on its next phase of growth
The Indian rupee slipped by 1 paisa to 82.10 against the US dollar (22.37 against the UAE dirham) in early trade on Wednesday, tracking the strong dollar and withdrawal of foreign funds from Indian equities.
An upward movement in crude price also weighed on the South Asian currency, forex traders said.
At the Indian interbank foreign exchange, the rupee opened lower at 82.13 but regained further to touch the peak of 82.07. The currency later turned flat and traded at 82.10 against the greenback, registering a fall of 1 paisa from its previous close.
On Tuesday, the rupee settled at 82.09 against the dollar.
"Upswings went soft after achieving the objective of 82.15, which we have been playing for the last two days. We are encouraged to pursue extended upsides aiming 82.2-82.25, and would rather do that on dips, but slippage past 82.04 may make 81.9 vulnerable again," Anand James, Chief Market Strategist at Geojit Financial Services, said in his USD-INR outlook.
Meanwhile, the dollar index, which gauges the greenback's strength against a basket of six currencies, was up 0.02 per cent at 102.57.
Crude oil price benchmark Brent crude was trading 0.26 per cent higher at $76.10 per barrel.
In the Indian equity market, the 30-share BSE Sensex advanced 185.17 points or 0.29 per cent to 63,512.87, while broader NSE Nifty inched up 38.75 points or 0.21 per cent to 18,855.45.
Foreign Institutional Investors (FIIs) were net sellers in the capital markets on Tuesday as they sold shares worth Rs19.42 billion, according to exchange data.
(With inputs from PTI)
ALSO READ:
Tecom embarks on its next phase of growth
Loyalty schemes, AI and customer retention will be key
Transaction value expected to hit $29.75 billion this year
Overall volume of digital payments in Mena has grown nearly seven-fold since 2020
In 2023, total consumption of gold in the UAE reached 39.7 tonnes
Maritime India Vision 2030 envisions investment of Rs1.25 trillion
Profitability, cash flow and capital expenditure guidance reiterated
Swiss pharma firm has an annual capacity of 250 million tablets